Interview

The Right CDMO Can Unlock Faster Drug Development

Format: Video | Document type: Interview | Promoted Content

This content is provided by Lonza Small Molecules, and any views and opinions expressed do not necessarily reflect those of www.outsourcing-pharma.com

The Right CDMO Can Unlock Faster Drug Development

Related categories: Drug delivery, formulation Phase I-II

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive experience. That is where choosing the right CDMO comes in.

The key to delivering projects sooner than anticipated lies in the ability of your CDMO to advise, adapt and adjust to the demands of any given phase.

In this insightful podcast, discover how the right CDMO can open the doors vital to achieving your objectives.

Latest content from Lonza Small Molecules

Lonza de-risks drug development through PBPK

Paid for and in partnership with Lonza Small Molecules

The opportunity to de-risk drug development through PBPK

No company wants to progress a molecule through to the clinic only to suffer a bad readout. PBPK modeling services allow companies to predict what absorption challenges may arise in trials, and plan ways to mitigate them.

Related resources from Lonza Small Molecules

Supplier info centre